SUTRO BIOPHARMA, INC.

(STRO)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
6.600 USD   +6.62%
07:25aBerenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Rating
MT
08/08SUTRO BIOPHARMA : Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones - Form 8-K
PU
08/08SUTRO BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sutro Biopharma : 22nd Annual Federation of Clinical Immunology Societies (FOCIS) Meeting 2022– Abstract and Poster Presentation

06/23/2022 | 09:26pm EDT

Presenting Author:

Kristin Bedard, PhD
VP Discovery
Sutro Biopharma
South San Francisco, California, United States

Abstract Text: In recent years, combination therapies of antibody-drug conjugates (ADCs) and immune system activators have garnered much interest due to their potential to unlock greater durable clinical benefit. Recently, we demonstrated that STRO-002, our novel anti-folate receptor alpha (Folα)ADC currently in Phase I clinical trials, can engage the immune system through induction of immunogenic cell death (ICD). We further showed that by complementing the ICD-inducing property of STRO-002 with combination treatment with Avelumab, we could enhance infiltration of CD8+ T cells into the tumor and generate potent anti-tumor immunity. To develop the combination concept further, we leveraged Sutro's breakthrough XpressCF+TM cell-free technology, which utilizes precise site-specific conjugation to generate complex molecules, to engineer the immunostimulatory ADC (iADC), a next-generation ADC molecule that combines tumor-targeted cell killing and immune activation in a single modality. Using murine MC38 tumors engineered to express human FolRα, we demonstrated that delivery of a hemiasterlin/TLR agonist dual-conjugate anti-FolR iADC resulted in a more robust anti-tumor response compared to either modality administered alone. This improved response was associated with innate immune cell activation and increased CD8+ T cell infiltration in the tumor. Moreover, a greater number of complete responses was also observed following treatment with the anti-FolR iADC, and complete responders developed broad and robust immune memory that was able to reject MC38-hFolR rechallenge in a CD8+ T cell-dependent manner and parental MC38 rechallenge. Thus, the iADC concept unites two complementary mechanisms of tumor control in a single molecule to attain greater therapeutic benefit.

Disclaimer

Sutro Biopharma Inc. published this content on 23 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 June 2022 01:25:04 UTC.


© Publicnow 2022
All news about SUTRO BIOPHARMA, INC.
07:25aBerenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Ra..
MT
08/08SUTRO BIOPHARMA : Reports Second Quarter 2022 Financial Results, Business Highlights and A..
PU
08/08SUTRO BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
08/08Sutro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months En..
CI
08/08Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q2 Revenue $28.1M
MT
08/08Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and ..
AQ
08/03Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
AQ
07/27Sutro Biopharma Achieves 'First in Human' Milestone in Cytokine Derivatives Collaborati..
AQ
07/26SUTRO BIOPHARMA, INC. : Other Events (form 8-K)
AQ
07/26Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives..
AQ
More news
Analyst Recommendations on SUTRO BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 53,4 M - -
Net income 2022 -155 M - -
Net cash 2022 120 M - -
P/E ratio 2022 -2,14x
Yield 2022 -
Capitalization 344 M 344 M -
EV / Sales 2022 4,20x
EV / Sales 2023 9,06x
Nbr of Employees 234
Free-Float 87,4%
Chart SUTRO BIOPHARMA, INC.
Duration : Period :
Sutro Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUTRO BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 6,60 $
Average target price 27,00 $
Spread / Average Target 309%
EPS Revisions
Managers and Directors
William J. Newell President, Chief Executive Officer & Director
Edward C. Albini Chief Financial Officer & Secretary
Connie L. Matsui Chairman
Henry Heinsohn Vice President-Technology & Innovation
Trevor Hallam Chief Scientific Officer & President-Research
Sector and Competitors
1st jan.Capi. (M$)
SUTRO BIOPHARMA, INC.-58.40%291
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.94%40 375